Sarms Powder Muslce Building ACP-105 CAS NO.899821-23-9

  • CasNo899821-23-9
  • Molecular FormulaC16H19ClN2O
  • Purity99.5%
  • AppearanceWhite Powder
Inquiry

Product Details

Quick Details

  • CasNo: 899821-23-9
  • Molecular Formula: C16H19ClN2O
  • Appearance: White Powder
  • Delivery Time: 3days after we receive the payment
  • Throughput: 1000|Kilogram|Month
  • Purity: 99.5%

Sarms Powder Muslce Building ACP-105 CAS NO.899821-23-9

1. Product Name: ACP-105

2. CAS NO.: 899821-23-9

3. Purity: 99% min

4. Standard: USP

5. MF: C16H19ClN2O

6. Appearance: white or almost white crystalline powder

 

Product Details

ACP-105, a novel non-steroidal SARM. It is shown to be as potent and efficacious as testosterone in in vitro assays without interaction at other hormone receptors. Moreover, ACP-105 demonstrates potent anabolic effects on muscle and bone with minimal effect on prostrate in preclinical models. ACP-105 is often a non-steroidal and selective androgen receptor agonist. ACP-105 belongs to a class of molecules called selective androgen receptor modulators (SARMs). SARMs may advance the standard of answer to a variety of disorders including muscle-wasting conditions and osteoporosis, with fewer unwanted effects as compared with current treatments based on testosterone replacement.

 

Item

Value

CAS No.

899821-23-9

Other Names

ACP 105

MF

C18H18N2O

Place of Origin

China

 

Shaanxi

Type

Immune Function Agents

Grade Standard

Food Grade, Medicine Grade, Tech Grade

Brand Name

XAZB

Model Number

ACP 105

Purity

99%

Product Name

ACP 105

Appearance

White fine powder

Assay

99.0~101.0%

MOQ

5gram

Package

Aluminum Foil Bag

Function

bodybuliding

Payment

TT.Western Union

Sample

Availiable

Price

Negotiable. Depends on quantity

 

Funcation

Anabolism - promotion and growth of lean muscle tissue and mass. This is extremely important for the individual suffering from a muscle wasting disease. It is the muscle wasting that at times can lead to the demise of the patient even before the disease itself.

1) Increases in strength - again, excellent for those suffering from muscle wasting diseases. Increased bone density and strength - highly beneficial to the osteoporosis patient. SARMS may prove to be one of if not the most effective osteoporosis treatments available, although official data is still inconclusive.

2) Fat Loss - medications with strong androgen binding affinity have been shown to promote lipolysis. How significant these six SARMS are in this regard is inconclusive.

3) Low to No Virilization - this is highly important to women. Many compounds (anabolicandrogenic steroids) while the same benefits of anabolic steroids can apply to women as they do men, there is often the issue of virilization.

4) Endurance & Conditioning - All of the pre-clinical SARMS should have a level of positive effect on muscular endurance as well as overall physical conditioning. The level of effectiveness in such regards is dependent on the SARM in question and data is still inconclusive to quantify the total effects.

5) Nutrient Efficiency - All of the pre-clinical SARMS should have a positive impact on nutrient efficiency to one degree or
another. This refers to the ability of the body to make better use of the nutrients it consumes.

 

Application

 

ACP-105 is a drug which acts as a potent, orally active growth hormonesecretagogue, mimicking the GH stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including growth hormone and IGF-1, but without affecting cortisol levels. It is currently under development as a potential treatment for reduced levels of these hormones, such as in growth hormone deficient children or elderly adults, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty in the elderly. It also alters metabolism of body fat and so may have application in the treatment of obesity.